Artiva Biotherapeutics vs aTYR PHARMA
ARTV and ATYR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARTV and ATYR compare
aTYR PHARMA is the larger company, worth 2.6 times as much as Artiva Biotherapeutics ($489M against $189M).
Artiva Biotherapeutics scores higher on the StockData Score (8 against 5 for aTYR PHARMA), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARTV | ATYR |
|---|---|---|
| Size and price | ||
| Market cap | $189M | $489M |
| Share price | $3.86 | $4.99 |
| Change, 1 year | 18.8% | 563% |
| Change, 5 years | – | −98.5% |
| Beta (5Y) | 4.84 | – |
| Employees | 104 | 58 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.5× (better) | 10.0× |
| FCF yield | −40.8% | −11.2% (better) |
| Growth | ||
| Revenue growth, 5Y average | – | −55.1% |
| Profitability | ||
| Return on equity | −36.6% (better) | −98.4% |
| Return on invested capital | −3203% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 24.16 (better) | 5.12 |
| Altman Z-score | 4.16 (better) | −0.96 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 83.2% | 41.4% |
| Held by insiders | 68.3% | 2.6% |
| Insider net buying, 12 months | $106M (better) | $43.7K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 19.0% | 0.31% |
Go deeper
- ARTV stock overview
- ARTV income statement
- ARTV valuation and score
- ATYR stock overview
- ATYR income statement
- ATYR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.